Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with significant revenue growth and reduced R&D expenses. The Q&A section highlights a refined strategy and optimistic guidance for future growth, despite some vague responses. The company is targeting high-volume accounts and has a path to profitability, although not immediate. The strategic plan and market expansion efforts, including European approval, suggest positive momentum. However, some risks remain, such as supply chain scalability and clinical trial outcomes. Given the small-cap nature of the company, the overall sentiment is positive, with potential for a stock price increase of 2% to 8%.
Key Financial Performance
Q4 2025 Net Revenue $48 million, compared to $47 million in Q4 2024, reflecting a slight increase year-over-year.
Full Year 2025 Net Revenue $184 million, compared to $76 million in 2024, reflecting a significant increase due to the first full year of RYTELO commercial availability.
Gross to Net Deductions 17.7% for 2025, compared to 14.5% in 2024, due to increased volume, wider 340B utilization, and expanded GPO contracting.
Research and Development Expenses $74 million for 2025, compared to $104 million in 2024, a decrease due to lower clinical trial costs and manufacturing expenses after RYTELO approval.
Selling, General and Administrative Expenses $159 million for 2025, compared to $146 million in 2024, an increase due to higher sales and marketing employee costs and marketing program investments.
Total Operating Expenses $255 million for 2025, in line with guidance of $250 million to $260 million.
Cash and Marketable Securities $400 million as of December 31, 2025, compared to $503 million as of December 31, 2024, reflecting a decrease due to operational expenses and investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
RYTELO commercialization: RYTELO's fourth quarter net revenue was $48 million, and full year 2025 net revenue was $184 million. The company expects RYTELO net revenue for 2026 to be between $220 million and $240 million. RYTELO's growth strategy includes increasing awareness among U.S. healthcare professionals, expanding in-person and digital presence, and growing research partnerships.
Market expansion for RYTELO: The company is focusing on second-line lower-risk MDS patients, estimated to be approximately 8,000 in the U.S. European approval allows engagement outside the U.S. The commercial strategy includes targeting high-volume community accounts and leveraging digital marketing channels.
Operational efficiencies: Total operating expenses for 2025 were $265 million, in line with guidance. For 2026, operating expenses are projected to decrease to $230 million-$240 million. The company completed a strategic restructuring in December 2025, reducing headcount and aligning resources to growth priorities.
Strategic restructuring: The company completed a strategic restructuring in December 2025, reducing workforce and aligning financial resources to growth priorities. This is expected to streamline operations and support long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges risks and uncertainties related to forward-looking statements, including regulatory hurdles and compliance with FDA and NCCN guidelines.
Financial Risks: Operating expenses for 2025 were high at $255 million, and while a reduction is planned for 2026, there is a risk of financial strain if revenue growth does not meet expectations. Additionally, gross-to-net deductions are expected to increase, potentially impacting profitability.
Market Competition: The movement of luspatercept into the first-line setting creates competitive pressure for RYTELO in the second-line market. The company must ensure RYTELO's differentiation and adoption in this competitive landscape.
Supply Chain and Operational Risks: The company faces risks related to the scalability of its operations, including the need to manage increased demand for RYTELO and potential supply chain disruptions.
Strategic Execution Risks: The success of the RYTELO commercialization strategy depends on effective execution of marketing, education, and engagement initiatives. Failure in these areas could hinder market penetration and revenue growth.
Clinical and Scientific Risks: The IMpactMF trial's interim analysis is a critical milestone, and any negative outcomes could impact the company's strategic plans and investor confidence. Additionally, treatment-emergent cytopenias associated with RYTELO could pose challenges in clinical adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
RYTELO net revenue expectations for 2026: $220 million to $240 million, with the underlying assumption of driving consistent RYTELO quarter-over-quarter demand growth.
2026 total operating expenses: Projected to be between $230 million and $240 million, a roughly $20 million year-over-year reduction at the midpoint.
Gross to net deductions for 2026: Expected to be in the high teens to low 20s.
Research and development expenses for 2026: Expected to decrease slightly, primarily due to lower labor costs driven by a decrease in headcount as a result of the workforce reduction in December 2025, partially offset by higher clinical trial costs related to potential ISTs.
Selling, general and administrative expenses for 2026: Expected to decrease, primarily due to lower G&A labor costs driven by a decrease in headcount as a result of the workforce reduction in December 2025, partially offset by higher marketing costs due to continued investment in RYTELO commercialization strategy.
IMpactMF trial in relapsed/refractory myelofibrosis: Projected to reach the interim analysis death event trigger in the second half of 2026. Overall survival is the primary endpoint, with a base case planning perspective for progression to the final analysis in the second half of 2028.
Real-world evidence data for RYTELO: Initial data expected to be available in the second half of 2026.
European approval for RYTELO: Provides the ability to engage ex U.S. markets in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the commercial or physician behavioral milestones to watch for in the first half of the year to ensure growth inflection is on track?
A:The company is focused on executional plans with a refined strategy targeting high-volume accounts and impactful messaging. They are reiterating guidance of $220 million to $240 million in top-line growth, compared to $184 million in 2025. Q4 demand growth of 9% is an important forward-looking metric.
Q:How many second-line patients are currently targeted, and what is the proportion to third-line patients?
A:The company targets approximately 8,000 second-line patients. Around one-third of patients are coming from first and second lines, with a focus on second-line patients due to recent NCCN guideline updates favoring RYTELO as a preferred second-line agent.
Q:What is the cadence for translating demand growth and increased prescribing accounts into revenue?
A:Demand growth and increased prescribing accounts (150 new accounts in Q4) are key metrics. The company is focusing on high-volume community accounts and academic medical centers to drive consistent quarter-over-quarter growth in 2026.
Q:How many ordering accounts could there potentially be at peak, and is there a path to profitability in 2026?
A:The company sees significant potential for growth in ordering accounts, especially in the community setting (80% of patients). While there is a path to profitability, the focus in 2026 is on investing in commercial strategy and ISTs rather than achieving profitability.
Q:What percentage of patients in the first and second-line setting are currently on therapy, and what is needed to meet guidance?
A:Approximately 30% of patients in the first and second-line setting are on therapy. To meet guidance, the company needs more first-time users and repeat customers, particularly in high-volume accounts.
Q:To what extent is EVO seen as a second-line competitor, and what is the treatment paradigm for patients failing frontline luspatercept?
A:With luspatercept moving to the first line, ESAs are less effective post-luspatercept. Physicians are shifting to imetelstat as the preferred second-line drug. The market shift and NCCN guidelines favor the company’s focus on second-line patients.
Q:What are the plans for European approval and commercialization strategy?
A:The company has European approval but is focused on understanding HTA processes and negotiating pricing with large countries. They are also exploring partnerships for commercialization while prioritizing U.S. growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of potential ordering accounts at peak and the exact path to profitability. They also used vague language regarding the timing and impact of demand growth translating into revenue, as well as the European commercialization strategy, which remains in exploratory phases.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Medical
Corporate Affairs
Development Chief
Executive VP
Harout
IMpactMF trial
ISTs
Medical Officer
Officer Chief
President Investor
Relations Corporate
base
care professional
care provider
community center
community engagement
decrease headcount
discipline
emphasis
engagement volume
evidence generation
headcount workforce
health care
hematology community
interest community
labor decrease
line patient
line risk
opportunity RYTELO
patient field
restructuring
risk uncertainty
sound
term value
workforce reduction
world evidence
world experience
GERN Transcript
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary indicates strong financial performance with significant revenue growth and reduced R&D expenses. The Q&A section highlights a refined strategy and optimistic guidance for future growth, despite some vague responses. The company is targeting high-volume accounts and has a path to profitability, although not immediate. The strategic plan and market expansion efforts, including European approval, suggest positive momentum. However, some risks remain, such as supply chain scalability and clinical trial outcomes. Given the small-cap nature of the company, the overall sentiment is positive, with potential for a stock price increase of 2% to 8%.
Geron Corporation (GERN) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals several negative factors: a 3% demand decrease for RYTELO, high operating expenses, and competitive pressures. While there is a significant increase in net product revenue, the timeline for the IMpactMF Phase III trial is lengthy, delaying potential market impact. The Q&A section highlights management's avoidance of specific guidance, which may concern investors. Although there is a 15% growth in prescribing accounts, the overall sentiment is negative due to financial pressures, competitive landscape, and lack of clarity on future growth timelines.
Geron Corporation (GERN) Q2 2025 Earnings Call Transcript
Unknown8-6
The earnings call summary and Q&A reveal mixed sentiments. While there is positive news about the demand growth for RYTELO and strategic efforts to engage KOLs, the decline in net revenues and lack of specific guidance are concerning. The stable expenses and cash position are neutral factors. The Q&A section shows cautious optimism but also highlights management's reluctance to provide specific data. Given the market cap, the overall impact is likely neutral, with a slight lean towards positive due to the strategic focus and potential demand growth.
Geron Corporation (NASDAQ:GERN) Q1 2025 Earnings Call Transcript
Unknown5-8
The earnings call presents mixed signals: while there is a decrease in RYTELO's net revenue and competition risks, the company maintains a strong cash position and expects continued momentum. The EPS beat expectations, but the lack of a shareholder return plan and leadership uncertainties are concerning. The Q&A revealed management's evasiveness on some issues, which may cause investor apprehension. Given these factors and the market cap of $2.63 billion, the stock price is likely to remain stable, resulting in a neutral prediction.
GERN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
